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which in turn could support the justiﬁcation of HSCT
pharmacy services.545
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Background: Sulfamethoxazole/trimethoprim (SMX/TMP) is
the current gold standard for PCP prophylaxis in hemato-
poietic stem cell transplant (HSCT) patients. There are
several second line options for prophylaxis but many,
including intravenous (IV) pentamidine, have not been
proven to be as effective or as safe as SMX/TMP in the pe-
diatric HSCT population. There is increasing use of IV pen-
tamidine in the pediatric HSCT population, as it is easily
given once monthly, with no issues regarding compliance or
vomiting. However, there are limited published data to
support safety and efﬁcacy of this approach. This study was
aimed to determine the safety and efﬁcacy of IV pentamidine
in preventing PCP infection in our pediatric HSCT patients.
Methods: A retrospective chart review was conducted with
IRB approval to evaluate all HSCT patients at Cincinnati
Children’s Hospital Medical Center (CCHMC) that received at
least one dose of IV pentamidine from January 2010 to July
2013. The primary outcome, pentamidine efﬁcacy, was
evaluated through lack of breakthrough PCP infection. The
secondary outcome, pentamidine safety, was evaluated by
adverse events leading to pentamidine discontinuation.
Results: Total of 285 HSCT patients received at least one dose
of IV pentamidine and were included in the ﬁnal analyses.
Median age of patients was 5 years (range: 0.2 to 32 years).
Patients were on pentamidine prophylaxis for a median of 5
months (range 1-44 months). Only 1 patient developed
breakthrough PCP infection while receiving IV pentamidine
prophylaxis (0.35%). Two patients were diagnosed with
toxoplasmosis while receiving pentamidine prophylaxis
(0.7%). Twenty patients (7%) experienced an adverse event
leading to discontinuation of pentamidine, with tachycardia
being the most common adverse event leading to discon-
tinuation of pentamidine. The rate of adverse effects seen
with pentamidine is comparable to that seen in patients
receiving SMX/TMP prophylaxis which is associated with
adverse effects ranging from 3.1-59%.
Conclusion: In a three year time span only 1 patient
(0.35%) receiving IV pentamidine prophylaxis had a
breakthrough PCP infection. Although SMX/TMP is
considered ﬁrst line for PCP prophylaxis, based on the
results of this study, IV pentamidine should be considered
a safe and effective alternative in pediatric HSCT patients.
Of note, pentamidine does not provide toxoplasmosis
suppression, a consideration for children considered at
high risk of reactivation.547
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Background: Stem cell transplant patients who are hepatitis
B negative at the time of transplant and receive stem cells
from a hepatitis positive donor have a higher risk of liver
related post-transplant complications and hepatitis viral
positivity. The use of lamivudine has been documented in the
literature as chemoprophylaxis for preventing viral reac-
tivation in positive patients and also surface antigen negative
patients receiving stem cell product from hepatitis positive
donors. The expected duration of chemoprophylaxis with
lamivudine therapy is multiple months following stem cell
transplant. This is a case series of using a two dose course of
hepatitis B immune globulin, without lamivudine, for the
prevention of viral seroconversion in stem cell transplant
recipients.
Methods: This is a single center retrospective chart review of
three pediatric stem cell transplant patients who were pre-
scribed hepatitis B immune globulin for prophylaxis of
seroconversion of hepatitis B. Hepatitis B immune globulin
0.06mL per kilogram was administered as two doses, on day
-1 or day 0, and repeated four weeks later. All patients
received allogeneic transplantation from matched related
donors, found to be positive for hepatitis B prior to stem cell
harvest. Diagnoses for stem cell transplant of the patients
were acute lymphoblastic leukemia, congenital myeloﬁbrosis
and cartilage hair hypoplasia. Patient age ranged from 1 to 17
years.
Results: At median of 20 months follow up (range 12-32
months), no patients were reported to have a positive hep-
atitis B DNA after stem cell transplant. No cases of veno-
occlusive disease of the liver were observed. This small case
series may present an alternative, simpler prophylaxis
regimen that is effective at preventing hepatitis viral trans-
mission during stem cell transplant.548
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Background: High-dose chemotherapy with autologous
hematopoietic stem cell transplantation (auto-HCT) can be
an effective treatment for systemic light chain amyloidosis
(AL). However, signiﬁcant morbidity may occur in AL pa-
tients undergoing peripheral blood stem cell (PBSC) mobili-
zation, especially if they have cardiac or renal involvement.
Reported complications include ﬂuid overload, cardiac ar-
rhythmias, bleeding events, and infections.
Methods: We identiﬁed 101 patients with AL who under-
went PBSC mobilization and collection with ﬁlgrastim at a
dose of 10 mcg/kg/day between 2006 and 2013. Fifteen pa-
tients (15%) also received plerixafor at a dose of 0.16-0.24mg/
kg/day after at least 4 days of ﬁlgrastim. The primary
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(AE) during PBSC mobilization and collection. AE included
weight gain greater than 2%, cardiac arrhythmias/events,
hemorrhagic or thromboembolic events, failure to complete
PBSC collection, and death.
Results: The median age of patients was 60 years and me-
dian serum creatinine was 1.09 mg/dL. Fifteen patients (15%)
had cardiac involvement, 45 patients (45%) had renal
involvement, and 21 patients (21%) had both cardiac and
renal amyloid involvement. Ninety-two patients (91%) suc-
cessfully collected a minimum of 2 x 106 CD34 cells/kg and
proceeded to auto-HCT. Nine patients (9%) failed to com-
plete initial PBSC mobilization attempt due to signiﬁcant
toxicity and 7 patients (7%) were never able to proceed to
auto-HCT. Four patients (4%) died during the peri-mobili-
zation period, with 3 deaths attributed to sepsis/multi-or-
gan failure. Sixty-one patients (60%) developed weight gain
>2% of baseline weight. Seven patients (7%) experienced a
cardiac event (5 atrial ﬁbrillation/tachyarrhythmias, 1
myocardial infarction, and 1 hypertensive urgency). Five
patients (5%) had a thromboembolic event (4 deep venous
thromboses and 1 pulmonary embolism). Three patients
(3%) developed a signiﬁcant bleeding event (1 central ner-
vous system and 2 gastrointestinal). Because of high risk for
complications during PBSC mobilization, 17 patients (17%)
underwent PBSC mobilization as an inpatient. Furthermore,
14 patients (14%) began the mobilization process as an
outpatient but were subsequently admitted for
complications.
Conclusion: PBSC mobilization and collection in AL patients
can be associated with signiﬁcant morbidity, with almost
10% of patients unable to complete collection, and peri-
mobilization mortality of almost 4%. Selected patients may
beneﬁt from hospitalization during PBSC mobilization and
collection.TRANSPLANT NURSING ADMINISTRATION549
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
As increasingly more complex hematopoietic stem cell
transplants (HSCT) are performed there is a need to
improve continuity of care and quality outcomes for in-
patients. A shared leadership approach was use to on-board
four Clinical Nurse Leaders (CNLs) to a 48-bed HSCT unit in
a novel patient care delivery system as part of an institu-
tional roll out. Each CNL functioned as the primary lead
over staff and patients assigned to 12-bed pods in a patient-
centered care delivery approach called Primary Team
Nursing (PTN). The purpose is to discuss nurse sensitive
quality and patient satisfaction outcomes following the
implementation of PTN using CNLS on a large inpatient
stem cell transplant unit.
Methods, Intervention, & Analysis: Four CNLs trained with
bedside nurses learning the care of HSCT patients on a 48-bed unit over a 3-month period, and were then moved into
the CNL role overseeing teams of nurses and assistants
working on 12-bed pods with the implementation of PTN.
Quality and patient satisfaction data were trended prior to
and following the implementation of PTN. Additionally team
based outcomes were evaluated using TeamSTEPPS assess-
ment tools.
Findings & Interpretation: Metrics indicate signiﬁcant im-
provements in most nurse sensitive quality indicators
including patient satisfaction, fall reduction, hourly round-
ing, and CLABSI. Additionally TeamSTEPPS assessments per-
formed at intervals throughout the ﬁrst year of
implementation show improvement across the domains of
team structure, leadership, mutual support and
communication.
Discussion & Implications: Using CNLs as the team leader in
the Primary Team Nursing Model may contribute to
enhancing quality and continuity of care for complex HSCT
patients.550
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Topic Signiﬁcance & Study Purpose/Background/
Rationale: The shift of responsibilities to the outpatient
arena for patients and caregivers has challenged educators to
expand information accessibility from onsite education to
easily accessible internet resources. Effective education
keeps patients safe by providing caregivers speciﬁc infor-
mation when needed. Caregivers expect to get the trust-
worthy information from doctors and nurses as well as
online. Most caregivers have mobile devices (Pew 2013) and
increasingly rely upon the internet for information (Longa-
cre, 2013).
Methods, Intervention, & Analysis: Ongoing pre/post
Program Evaluation surveys are available. We developed a
multiplatform strategy utilizing social media (Facebook),
online video library, live streaming classes, online patient
manuals, and a RN monitored phone line in addition to
traditional formats such as a foundation class focusing on
post-transplant in the home. This approach provides ac-
cess to speciﬁc personalized information anywhere. These
approaches allow accessibility unimaginable a few years
ago.
Online distribution of patient manuals ensures current
information at home. Video links are contained in online
manuals. The core transplant videos include clinic orienta-
tion, managing care at home, CVC care, donor information,
long-term follow up, food safety, and relaxation. There are
over 70 videos in the online library. Patients and families use
the videos in anticipation of treatment as well as for review
of material.
Findings & Interpretation: The presentation will include
data from three sources: Facebook analytics (3000 monthly
interactions), ongoing surveys from program evaluations and
from a research protocol. Survey comments like “have PDFs
of caregiver manuals online” and “have videos online”
guided development. Results indicate preference for
personalized RN/MD instruction, classes, andmanuals (>4.5/
5) over generic pamphlets (3.7/5). Many patients have
rotating caregivers or out of town family members who rely
upon online materials.
